Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.

Concentration

1.0mg / ml

Formulation

Supplied at 1.0mg / mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage

Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

Synonyms

AI325008, BAD_HUMAN, BBC 2, BBC2, BBC6, Bcl 2 Antagonist of Cell Death, Bcl 2 Binding Component 6, BCL X / BCL 2 Binding Protein, BCL X Binding Protein, Bcl XL/Bcl 2 Associated Death Promoter, Bcl-2-binding component 6, Bcl-2-like protein 8, Bcl-XL/Bcl-2-associated death promoter, Bcl2 antagonist of cell death, BCL2 antagonist of cell death protein, BCL2 associated agonist of cell death, Bcl2 Associated Death Promoter, BCL2 binding component 6, BCL2 binding protein, Bcl2 Like 8 Protein, Bcl2-L-8, BCL2L8, Proapoptotic BH3 Only Protein

Suitable Secondaries

See all Anti-Rabbit IgG Secondaries →

Disclaimer

This product is for research use only. It is not intended for diagnostic or therapeutic use.

Scientific Validation Data (2)

Enlarge Image

Figure 1: Anti-BAD (Ab-155) Antibody (A36523)

Western blot analysis of extracts from 293 cells using BAD (Ab-155) Antibody #21064 and the same antibody preincubated with blocking peptide.

Enlarge Image

Figure 2: Immunohistochemistry - Anti-BAD (Ab-155) Antibody (A36523)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using BAD (Ab-155) Antibody #21064 (left) or the same antibody preincubated with blocking peptide (right).

Citations (1)

View Publication

Loss of Bad expression confers poor prognosis in non-small cell lung cancer.

References: Anti-BAD (Ab-155) Antibody (A36523)

Abstract:

Proapoptotic BH-3-only protein Bad (Bcl-Xl/Bcl-2-associated death promoter homolog, Bad) initiates apoptosis in human cells, and contributes to tumorigenesis and chemotherapy resistant in malignancies. This study explored association between the Bad expression level and prognosis in patients with non-small cell lung cancer (NSCLC). In our study, a cohort of 88 resected primary NSCLC cases were collected and analyzed. Bad expression level was determined via immunohistochemical staining assay. The prognostic significances of Bad expression were evaluated with univariate and multivariate survival analysis. The results showed that compared with normal lung tissues, Bad expression level significantly decreased in NSCLC (P < 0.05). Bad expression was associated with adjuvant therapy status. Loss of Bad independently predicted poor prognosis in whole NSCLC cohort and early stage subjects (T1 + T2 and N0 + N1) (all P < 0.05). Overall survival time was also drastically shortened for Bad negative phenotype in NSCLC patients with smoking history, especially lung squamous cell carcinoma (all P < 0.05). In conclusion, this study provided clinical evidence that loss of Bad is an independent and powerful predictor of adverse prognosis in NSCLC. Bad protein could be a new biomarker for selecting individual therapy strategies and predicting therapeutic response in subjects with NSCLC.

View Publication

Publishing research using Anti-BAD (Ab-155) Antibody (A36523)? Please let us know so that we can list the citation on this page.